Physician profile
Lily Park
NPI 1124333455
$10,088.80
in general payments reported to CMS, 2019-2025
28 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $371 · 2021: $1,065 · 2022: $2,829 · 2023: $2,186 · 2024: $1,712 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,162.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,385.18 | 2019-2025 | |
| Janssen Biotech, INC. | $1,483.16 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $689.46 | 2019-2024 | Otezla |
| Ucb, INC. | $563.50 | 2019-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $456.48 | 2020-2024 | Dupixent |
| Pfizer INC. | $455.86 | 2021-2024 | |
| Incyte Corporation | $454.08 | 2021-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $448.75 | 2020-2025 | Absorica Ld, Winlevi, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $442.31 | 2023-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $435.48 | 2021-2024 | Tremfya |
| Genzyme Corporation | $404.27 | 2022-2025 | |
| Galderma Laboratories, L.P. | $355.69 | 2019-2023 | |
| Lilly USA, LLC | $345.06 | 2021-2025 | Taltz, Ebglyss |
| Sanofi-Aventis U.S. LLC | $179.98 | 2021-2022 | |
| Leo Pharma INC. | $142.82 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $141.59 | 2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $124.04 | 2022-2023 | Siliq |
| Botanix Sb INC | $122.31 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.31 | 2022-2023 | Spevigo |
| Dermavant Sciences, INC. | $93.24 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $65.16 | 2022-2024 | |
| Helsinn Therapeutics (U.S.), INC. | $45.18 | 2022-2023 | Valchlor |
| Convatec INC. | $36.36 | 2024 | |
| Smith+Nephew, INC. | $28.61 | 2021 | |
| Kyowa Kirin, INC. | $28.48 | 2021 | |
| Organogenesis INC. | $20.84 | 2025 | Cygnus Dual |
| Genentech USA, INC. | $18.77 | 2023 | Erivedge |
| Mayne Pharma Commercial LLC | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.